Related Experiment Videos
Raloxifene does not prevent fibrinogen oxidation in vitro
Margit Blasbichler1, Arsineh Arakil-Aghajanian, Helmut Sinzinger
1Institute for Diagnosis and Treatment of Atherosclerosis and Lipid Disorders (ATHOS), Vienna, Austria.
Summary
Raloxifene, a selective estrogen receptor modulator (SERM), does not inhibit iron-mediated oxidation of fibrinogen in vitro. This suggests raloxifene may not protect against fibrinogen oxidation, unlike its known effect on LDL oxidation.
Area of Science:
- Biochemistry
- Pharmacology
- Protein Oxidation
Background:
- Protein modification is implicated in various pathophysiological processes.
- Raloxifene (SERM) is known to inhibit low-density lipoprotein (LDL) oxidation.
- Investigating raloxifene's antioxidant effects on fibrinogen oxidation is warranted.
Purpose of the Study:
- To determine if raloxifene inhibits in vitro iron-mediated oxidation of fibrinogen.
- To assess the potential antioxidant capacity of raloxifene against fibrinogen oxidation.
Main Methods:
- In vitro study of raloxifene's effect on fibrinogen oxidation.
- Tested concentrations of raloxifene (5, 10, 125 microM) and incubation periods (60, 120 min).
- Iron-mediated oxidation model used for fibrinogen.
Main Results:
- No evidence found that raloxifene inhibits iron-induced fibrinogen oxidation in vitro.
- Raloxifene's inability to oxidize fibrinogen may be due to its structure and fibrinogen's lack of lipophilic properties.
- The mechanism of raloxifene's action on LDL oxidation remains unclear.
Conclusions:
- Raloxifene does not inhibit fibrinogen oxidation in vitro, contrasting with its effect on LDL.
- Further in vivo studies are needed to determine the biological relevance of these findings.
- Raloxifene's antioxidant activity appears specific and does not extend to fibrinogen oxidation.